Biotech by short interest
Shares sold short and not yet covered, as reported to FINRA for the latest settlement date, as a percent of shares outstanding (market value divided by share price), not of the smaller float.
Scholar Rock Holding leads the 24 biotech ranked by short interest, at 19.2%, ahead of CRISPR Therapeutics (17.7%) and Twist Bioscience (14.4%). Figures as of the 30 Oct 2026 settlement date, from FINRA's short interest report, with shares outstanding from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Scholar Rock Holding19.2%
- Median
- 9.33%
- Combined market value
- SAR 3.14T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Short interest % ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock HoldingSRRK · Health Care | 19.2% | SAR 21.5B | SAR 176.05 | 4.11% up | 14% up | ||
| 2 | CRISPR TherapeuticsCRSP · Health Care | 17.7% | SAR 14.9B | SAR 153.90 | 2.19% up | 21% down | ||
| 3 | Twist BioscienceTWST · Health Care | 14.4% | SAR 29B | SAR 424.76 | 1.11% up | 340% up | ||
| 4 | Kodiak SciencesKOD · Health Care | 12.4% | SAR 23.8B | SAR 363.21 | 0.03% up | 396% up | ||
| 5 | Halozyme TherapeuticsHALO · Health Care | 12.0% | SAR 41.2B | SAR 361.56 | 0.44% up | 37% up | ||
| 6 | ImmunityBioIBRX · Health Care | 11.9% | SAR 26.5B | SAR 24.91 | 6.07% up | 193% up | ||
| 7 | RepligenRGEN · Health Care | 11.0% | SAR 40.7B | SAR 636.94 | 4.70% up | 5% up | ||
| 8 | ExelixisEXEL · Health Care | 10.5% | SAR 62.7B | SAR 256.76 | 0.07% down | 63% up | ||
| 9 | CG OncologyCGON · Health Care | 10.3% | SAR 26.7B | SAR 298.99 | 0.98% up | 85% up | ||
| 10 | Krystal BiotechKRYS · Health Care | 10.3% | SAR 33.8B | SAR 1,139.85 | 1.79% up | 46% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | 9.84% | SAR 38.9B | SAR 455.54 | 0.06% down | 87% up | ||
| 12 | VaxcytePCVX · Health Care | 9.70% | SAR 34.3B | SAR 216.40 | 2.88% down | 22% up | ||
| 13 | ImmunovantIMVT · Health Care | 8.96% | SAR 26B | SAR 125.83 | 1.01% up | 43% up | ||
| 14 | ModernaMRNA · Health Care | 8.20% | SAR 306.1B | SAR 756.63 | 2.46% down | 755% up | ||
| 15 | Adaptive BiotechnologiesADPT · Health Care | 7.09% | SAR 17.3B | SAR 106.68 | 0.18% down | 88% up | ||
| 16 | Revolution MedicinesRVMD · Health Care | 6.05% | SAR 128.8B | SAR 595.55 | 2.41% down | 131% up | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | 5.83% | SAR 61.4B | SAR 606.44 | 2.56% down | 20% up | ||
| 18 | Bio-TechneTECH · Health Care | 4.90% | SAR 42.8B | SAR 272.74 | 0.11% up | 26% up | ||
| 19 | BiogenBIIB · Health Care | 3.69% | SAR 137.8B | SAR 932.16 | 0.91% down | 49% up | ||
| 20 | QiagenQGEN · Health Care | 3.10% | SAR 38.4B | SAR 185.84 | 0.41% down | 12% up | ||
| 21 | AmgenAMGN · Health Care | 2.33% | SAR 906.1B | SAR 1,675.08 | 2.48% down | 34% up | ||
| 22 | argenxARGX · Health Care | 2.25% | SAR 224.1B | SAR 3,562.83 | 0.24% up | 4% up | ||
| 23 | Gilead SciencesGILD · Health Care | 1.72% | SAR 782.8B | SAR 631.14 | 1.17% down | 33% up | ||
| 24 | BioNTechBNTX · Health Care | 0.91% | SAR 78B | SAR 314.54 | 1.18% down | 16% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; short interest from FINRA, the owner and source of the data, as of the 30 Oct 2026 settlement date.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Source: FINRA. Short interest is the shares sold short and not yet covered as brokers reported them to FINRA for the 30 Oct 2026 settlement date; FINRA publishes it about seven business days later, so it is not today's figure. It is divided by shares outstanding worked out as the market value over the share price, both from the same quote — not by the float, so the percent reads lower than a percent of float would. For a company with more than one class of shares the market value covers every class, which lowers it further. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech rank first by short interest?
Scholar Rock Holding (19.2%), CRISPR Therapeutics (17.7%) and Twist Bioscience (14.4%) are the top three of the 24 biotech ranked by short interest as of the 30 Oct 2026 settlement date.
How many biotech are in this ranking?
24 are ranked by short interest.
What are these biotech worth together?
The 24 biotech ranked by short interest have a combined market value of SAR 3.14T as of the 30 Oct 2026 settlement date.
What does ranking by short interest measure?
Shares sold short and not yet covered, as reported to FINRA for the latest settlement date, as a percent of shares outstanding (market value divided by share price), not of the smaller float.
Learn how this ranking works
All markets guides →- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
Cite this page
Funkfolio, “Biotech by short interest”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=short-interest
Underlying data: FINRA short interest (the 30 Oct 2026 settlement date); Yahoo Finance.